Tongue cancer following hematopoietic cell transplantation for Fanconi anemia

Mattia Di Bartolomeo1 · Alexandre Anesi2 · Arrigo Pellacani1 · Sara Negrello3 · Annalisa Natale4 · Sabina Figurelli3 · Doriana Vaddinelli4 · Stefano Angelini5 · Luigi Chiarini2 · Riccardo Nocini6 · Paolo Di Bartolomeo4

Received: 3 April 2022 / Accepted: 16 May 2022 / Published online: 28 May 2022 © The Author(s) 2022

Abstract

Objectives The aim of this retrospective study was to determine the incidence and the clinical outcome of tongue cancer (TC) in patients affected by Fanconi anemia (FA) who received an allogeneic hematopoietic cell transplantation (HCT).

Materials and methods The patient database from the Bone Marrow Transplant Center of Pescara was reviewed to enroll FA patients. Patients’, donors’, HCT’s, and screening’s data were collected as well to look for the incidence and the treatment of TC.

Results Twelve patients affected by FA were identified. Three patients died for transplant-related causes. Five of nine surviving patients were diagnosed with TC at a median of 21.7 years since transplantation and at a median age of 32.10 years. Interestingly, no patient manifested graft-versus-host-disease (GvHD). The 28-year cumulative incidence function of TC was 46.9% (95% CI, 36.9–56.9%). Two patients were treated with chemotherapy alone, two patients were treated with surgery alone, and one with surgery followed by chemotherapy. Overall, 4 patients with TC showed a clinical course characterized by a marked aggressiveness of the tumor disease which led to death due to cancer progression between 2 and 13 months. One patient is surviving 8 months after diagnosis of TC.

Conclusions Our study confirms the high incidence of tumors and in particular tongue tumors in allotransplanted FA patients. A careful screening has to be life-long maintained.

Clinical relevance Considering the rarity of FA and the frailty of FA patients, this study may add important information for the cancer management of these patients.

Keywords Fanconi · Tongue · Squamous cell carcinoma · Oxidative stress · Bone marrow transplantation · Oral cancer

Introduction

Fanconi anemia (FA) is a rare genetically and phenotypically heterogeneous autosomal and X-linked recessive disorder characterized by a broad spectrum of congenital malformations, progressive bone marrow failure (BMF), the presence of spontaneous and induced chromosomal breakage, and a marked predisposition to both hematological (myelodisplastic syndrome and acute myeloid leukemia) and solid tumors, specifically squamous cell carcinoma of head and neck (HNSCC) and genital region [1]. Hematological abnormalities occur in at least 90% of FA patients at a median onset of 7 years. Patients with FA have significantly increased cancer susceptibility because of defective DNA repair, which is a major molecular phenotype of the disease. The risk of head and neck squamous cell carcinoma is > 500-fold higher among individuals with FA compared with the general population [2, 3]. Allogeneic hematopoietic cell transplantation (HCT) is the only proven potential curative therapy and many adjustment have been made over time to improve HCT survival in FA patients [4, 5].

HCT is indeed able to completely and definitively correct BMF. Nonetheless, HCT is unable to eliminate the cancer susceptibility of FA patients and actually increases it considerably. The reason lies in the chemo-radiotherapeutic treatments...
used in the conditioning therapy and in the possible manifestation of graft-versus-host disease (GvHD) [6, 7].

Among HNSCC, in FA patients, the main role is played by oral cavity cancers [8]. In particular, tongue cancers have a rising incidence, representing almost 60% of all oral cancers in FA patients [2].

In this retrospective study, we describe the occurrence and the clinical outcome of tongue cancer (TC) in 12 FA patients who received an allogeneic HCT.

Materials and methods

Study cohort

Our study included 12 consecutive patients with FA who received an allogeneic HCT between May 1986 and October 2013 at the Bone Marrow Transplant Center of Pescara, Italy. The study was approved by the local institutional review board. Informed consent for the transplant was obtained from all patients and donors or their legal guardians in accordance with the Declaration of Helsinki.

Data collection

Data were extracted from the Allogeneic Transplant Program Database of the Pescara Bone Marrow Transplant Center and included patient and donor demographic information (age, gender), hematologic disease diagnosis, donor relationship and HLA compatibility, stem cell source (either bone marrow, peripheral blood stem cells, or cord blood), drugs used in the conditioning regimen, and drugs used as GvHD prophylaxis. Other information regarding the post-transplant clinical outcome including engraftment, acute and chronic GvHD, survival, and most important complications were also obtained from the database. We examined both the incidence and the outcome of post-transplant TC.

Patient characteristics

Baseline patient clinical characteristics are shown in Table 1. The median age at time of transplant was 11.9 years (range, 5.2 to 19.1). In all cases, the diagnosis of FA was made by the presence of pancytopenia both in the peripheral blood count and in bone marrow aspirate associated with typical physical malformations. The diagnosis was confirmed by demonstration of increased chromosomal breakage in patient lymphocytes by the addition of diepoxybutane [9]. Indication for HCT was bone marrow failure in all cases. No patient showed any sign of myelodysplastic syndrome or leukemic transformation at time of transplant. Positive family history of FA was present in 2 patients, who were brothers and had two other brothers who died for progressive marrow failure due to FA.

Donor characteristics

Marrow donors were HLA genotypically identical siblings in 7 cases and 8/8 allele level HLA-matched unrelated donors in 3 cases. Two patients were transplanted with 5/6 allele HLA-matched unrelated umbilical cord blood (UCB) units. The donor median age was 19 years (range, 0 to 42). Five donors were males and 7 females.

Transplant procedure

Each recipient was given unique patient number (UPN). The day of transplant was designated as day 0. The patients were treated in a laminar air flow room and maintained in a program of skin and mucosal decontamination. Ten patients received a preparative regimen consisting of low-dose cyclophosphamide (CY) (total dose 20 mg/kg) and total body irradiation (TBI) (total dose 5 Gy given on 3 fractions over 2 days), as previously described. One patient (UPN 706) received a combination of CY (50 mg/kg) and fludarabine (120 mg/m²) and one patient (UPN 973) was given a combination of thiotepa (5 mg/kg), busulfan i.v. (9.6 mg/kg) and fludarabine (120 mg/m²). For GvHD prophylaxis, 4 patients received cyclosporine A (CSA) alone and 8 were given a combination of CSA and short-course methotrexate. Hemopoietic stem cell source was bone marrow in 10 cases and UCB in 2.

Definitions

Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count ≥ 0.5 x 10⁹/L and platelet engraftment as the first of 3 consecutive days with an absolute platelet count ≥ 25 x 10⁹/L without transfusion support. Transplant-related mortality (TRM) was defined as all causes of death occurring at any time after HCT and not related to the underlying disease. Acute GvHD (aGvHD) was diagnosed according to Glucksberg’s criteria, and chronic GvHD (cGvHD) according to the modified Seattle criteria (for categorization of cGvHD as clinical limited or clinical extensive) [7, 10]. Patient delay represents the time in months between the date the first symptoms were noted by the patient and the date of treatment.

Post-transplant cancer screening

In the first 5 years after transplantation, all patients were followed at least annually at the transplant center and every 2 to 3 years later or when a new clinical event appeared. They were constantly informed about the importance of
an accurate screening for common cancers and in particular of cancer of oral cavity using brochures illustrating the increased risk of developing cancer.

Information on second tongue cancer, including date of diagnosis, site of involvement, morphologic features, therapy, and outcome, were collected by a review of medical records provided either by the patients or by the physician who made the diagnosis and had taken care of them. All cases were staged according to the American Joint Committee on Cancer (AJCC) staging system [11]. Pathology and physician reports of each case of STC were reviewed centrally at the transplant center by a committee including the transplant expert, the pathologist, the head and neck surgeon, and the oncologist. If necessary, tumors were reclassified in the clinical and pathological extension.

Table 1  Clinical characteristics of patients at time of HCT

| UPN | Sex | Age years | Phenotypic anomalies                                                                 | Interval diagnosis HCT months | Previous therapy | N. of transfusions | RBC    | PLT     | Hgb g/dL | PMN × 10^9/L | PLT × 10^9/L |
|-----|-----|-----------|--------------------------------------------------------------------------------------|-------------------------------|------------------|--------------------|--------|---------|----------|---------------|---------------|
| 073 | M   | 13        | Café-au-lait spots, Short stature, Osteoporosis, Cryptorchidism, Renal ectopy          | 8                             | None             | 4                  | 0      | 7.1     | 450      | 68            |               |
| 082 | M   | 11        | Café-au-lait                                                                       | 27                            | None             | 2                  | 0      | 8.8     | 1400     | 48            |               |
| 122 | M   | 7         | Short stature, Hypoplastic thumb, Cryptorchidism, Clubfoot, Single kidney            | 9                             | None             | 2                  | 3      | 8.2     | 2400     | 29            |               |
| 183 | F   | 13        | Skin pigmentation, Short stature, Microcephaly, Clinodactyly                        | 16                            | Androgens        | 0                  | 0      | 8.7     | 1200     | 71            |               |
| 184 | M   | 14        | Café-au-lait spots, Short stature, Microcephaly                                    | 16                            | Androgens        | 1                  | 0      | 8.5     | 1300     | 81            |               |
| 230 | F   | 13        | Café-au-lait spots, Short stature, Microcephaly, Hearing loss                       | 105                           | Androgens, Steroids | 3                  | 0      | 8.2     | 650      | 61            |               |
| 328 | M   | 6         | Short stature, Microcephaly, Ear canal atresia, Single palmar sulcus                | 18                            | None             | 1                  | 0      | 8.6     | 900      | 27            |               |
| 333 | F   | 11        | Skin pigmentation, Microcephaly, Renal ectopy, Horseshoe kidney, Hearing loss       | 60                            | Androgens, Steroids | 0                  | 0      | 7.9     | 2300     | 61            |               |
| 346 | M   | 19        | Café-au-lait spots                                                                  | 107                           | None             | 0                  | 0      | 5.4     | 400      | 20            |               |
| 421 | M   | 5         | Café-au-lait spots, Short stature                                                  | 4                             | None             | 2                  | 2      | 6.6     | 540      | 9             |               |
| 701 | F   | 9         | Facial dysmorphia, Costal malformations, Hypoplastic thumb, Renal hypoplasia        | 25                            | None             | 0                  | 0      | 8.3     | 880      | 22            |               |
| 973 | F   | 12        | Café-au-lait                                                                        | 91                            | None             | 1                  | 0      | 10.9    | 700      | 32            |               |

Abbreviations: HCT, hemopoietic cell transplantation; UPN, unique patient number; M, male; F, female; RBC, red blood cell; PLT, platelet; Hgb, hemoglobin; PMN, polymorphonucleates

Statistical analysis

Categorical and continuous data were summarized by median (range) and frequency, respectively. Taking into consideration
death without occurrence of TC as competing risk, the probability of TC has been studied by fitting cumulative incidence function (CIF). Statistical analyses were performed with the use of R Statistical Software (version 3.3.3; R Foundation for Statistical Computing, Vienna, Austria).

Results

Transplantation

Eleven patients achieved full neutrophil and platelet engraftment after a median time of 14 days (range, 11–26) and 16 days (range, 11–35) after stem cell infusion, respectively. Acute GvHD affected 6 patients (grade I in 2, grade II in 2, and grade III in 2). Extensive cGvHD was diagnosed in 3 patients. Oral cGvHD was evident in 2 of them. Three patients (25%) died for transplant-related causes. One patient (UPN 346) died before engraftment on day 10 because of veno-occlusive disease of the liver, 1 patient (UPN 421) died on day 90 for aGvHD, and 1 patient (UPN 701) died on day 910 for cGvHD. One patient (UPN 073) died for accidental cause 8 years after transplantation. At time of data-censoring date (February 1, 2022), 3 patients out of 12 (25%) were living and doing well after 39 years (UPN 230), 25.6 years (UPN 328), and 8.1 years (UPN 973) after transplantation.

Incidence and outcome of cancer after transplantation

Five patients (2 males) developed TC at a median of 21.7 years (range, 18.4 to 28.8) since HCT. The 28-year CIF of TC was 46.9% (95% CI, 36.9–56.9%) (Fig. 1). Table 2 depicts details of patients who were diagnosed with TC. Of them, 3 had never been smokers and 2 had history of smoking and were smokers at time of TC. About

![Cumulative incidence function of tongue cancers in Fanconi anemia patients.](image)

Fig. 1

| UPN | Time to TC years | HT | CE | PE | HP grading | Stage | Patient delay months | Treatment | Status |
|-----|-----------------|----|----|----|-------------|-------|----------------------|-----------|--------|
| 082 | 18.4            | SCC | T2N0Mx | pT2cN0cM0 | G2 | II | 0 | Surgery, CH | Progression, dead after 13 months |
| 122 | 25.6            | SCC | T2N2cM1 | G3 | IVC | 24 | CH | Progression, dead after 2 months |
| 183 | 18.6            | SCC | T2N2cM0 | G3 | IVA | 6 | CH | Progression, dead after 4 months |
| 230 | 28.8            | SCC | T2N0M0 | pT1cN0cM0 | G2 | I | 9 | Surgery | Alive & well after 7 months |
| 333 | 21.7            | SCC | T3N0M0 | pT3pN3bcM0 | G2 | IVb | 5 | Surgery | Progression, dead after 7 months |

Table 2: Details of patients who were diagnosed with TC

Abbreviations: TC, tongue cancer; UPN, unique patient number; HT, histologic type; SCC, squamous cell carcinoma; CE, clinical extension; PE, pathological extension; HP, hystopathologic; CH, chemotherapy
alcohol consumption and drug abuse, only one patient was both moderate alcohol user and drug abuser at time of TC. No patient had ever shown signs of cGvHD and none was receiving systemic immunosuppressive therapy at time of. Histologic examination showed squamous cell carcinoma (SCC) in all cases. The median patient delay was 6 months (range, 0 to 24 months).

Two other patients were diagnosed with cancer other than TC. One male patient (UPN 328) was diagnosed with papillary thyroid carcinoma (T1N0M0) 12 years after transplantation for which he underwent total thyroidectomy and no other subsequent therapy. This patient was subsequently diagnosed with an ear skin melanoma 20 years after HCT which was radically excised with surgery. He is now in good health condition at 25 years since HCT with Karnofsky score of 100%. One patient (UPN 184) was diagnosed with SCC of the esophagus (cT2cN0cM0) at 21 years after HCT for which he was initially treated with radiotherapy followed by chemotherapy. One year later, the tumor disease reappeared in the same site with invasion of adjacent tissues and diffuse nodal metastases. The patient died 2 years after diagnosis of the cancer. To conclude, 1 patient (UPN 973) had a post-transplant outcome complicated by severe lung cGvHD. This patient is now living at 8 years after HCT without any immunosuppressive therapy but with a limited respiratory function and a Karnofsky score of 80%.

**TC case by case presentation**

**UPN 082** He presented to the outpatient clinic with an ulceration of the left lingual margin, with the histologic specimen confirming the diagnosis of a well-differentiated SCC. A left hemi-glossectomy was performed in a different surgical center, with clear surgical margins. No lymph node dissection and no adjuvant therapy were performed. Ten months after the surgery, the patient presented with a left cervical lymph node swelling. It was histologically diagnosed as a site of carcinoma recurrence. He underwent three courses of cisplatin and 5-fluorouracil-based chemotherapy. No tumor response was obtained, and the patient died 13 months since TC diagnosis.

**UPN 122** The patient showed a painful swelling of the left lingual margin, but as a consequence of his severe anxious depressive state, he refused any diagnostic approach for 24 months. Finally, he agreed to undergo a biopsy of the lingual lesion, which documented a well-differentiated SCC. Unfortunately, the disease showed multiple lung metastases. He received a palliative treatment with low-dose chemotherapy and died 2 months later.

**UPN 183** The patient, who was affected by severe mental retardation, showed a painful swelling of the right lingual margin. Six months since the first symptoms, the patient underwent a tumor biopsy that showed a moderately differentiated SCC. There was no data available regarding lymph node involvement. She received three courses of cisplatin and 5-fluorouracil-based chemotherapy, but no response was observed. The outcome was complicated by severe neutropenia followed by an idiopathic pneumonia which was the cause of death at 4 months since the TC diagnosis.

**UPN 230** She presented to the outpatient clinic with a painful swelling of the right lingual margin. During the clinical examination, a concomitant ulceration of the adherent gingiva in the fourth quadrant was observed (Fig. 2). A prompt biopsy of both lesions led to the diagnosis of two moderately differentiated SCC. Preoperative radiological examinations showed no cervical nor distant metastasis. The patient underwent partial tongue resection and partial mandibulectomy, with clear surgical margins. The mandibular defect was contextually reconstructed with a right facial artery musculo-mucosal (FAMM) flap. The patient is now
living and under strict clinical and radiological follow-up at 8 months post-operatively.

**UPN 333** The patient showed a painful swelling of the left lingual margin. Due to the actual COVID-19 pandemic, unluckily, a 5-month delay in tumor diagnosis was determined. During this time, the lingual swelling considerably grew in size (Fig. 3). Eventually, the patient underwent sub-total glossectomy with bilateral lymph node resection and tracheotomy. The histological result showed a moderately differentiated SCC with clear margins. Homolateral cervical lymph nodes were involved by tumor metastases. The poor general clinical conditions prevented any form of radiotherapy or chemotherapy and the patient died of cachexia 7 months after TC diagnosis.

**Discussion**

FA patients are known to be more prone to developing malignant tumors. It is believed that this predisposition is linked both to the congenital instability of the chromosomes present in these patients and to a possible immunodeficiency. Fortunately, the optimization of HCT techniques has led to a lengthening of life expectancy in patients with FA. This resulted in an improvement in the immune capabilities of these patients. However, HCT opened the door to the long-term complications of this pathology at the same time.

For example, it was possible to observe an incredible predisposition to develop solid malignancies. In a recent study by Risitano et al., overall survival at 30 years was 37% and the main cause of death was represented by cancer [12]. In particular, HNSCC are very common in patients with FA. It is believed that they are 500 times more likely to develop HNSCC than the general population [2]. It also has to be underlined that the worst DNA damage can lead to an earlier development of malignancies. In the literature, it has been reported that the median onset age of FA-HNSCC is 32 years, compared to a median age of 63 years old in the general population [13, 14]. Several aspects have to be discussed to assess the reasons behind this increased risk.

First of all, the role of oxidative stress has to be cleared. In fact, it has been shown that oxidative stress can play a role in pathogenesis of various diseases, such as other oral conditions or in neurodegenerative diseases [15, 16]. The formation of oxygen radicals increases indeed the potential damage to the DNA. In FA patients, the ability to recover is limited, and therefore, the damage to DNA can potentially determine a malignant transformation of oral cavity cells. These intriguing aspects have led to hypothesize the central role of mitochondrial dysfunctions in FA patients [17, 18]. Animal models have been proven very useful in studying the underlying mechanisms of many conditions, including FA [19, 20]. In this case, chemoprevention therapies have been tested in vivo to reduce oxidative stress, with promising results [21].

Among the sites of the oral cavity, it should be noted that the tongue is affected in 60% of cases. In the general population, this data drops to 10–20%. The reason may lie in the high replication rate of tongue mucosal cells, subjected to a continuous mechanical stimulus due to movement. It has been estimated that gingival epithelium turnover time is 41 to 57 days, while the turnover time for cells of the dorsal surface of the tongue is around 5 days [22, 23].

The higher turnover rate creates a statistical increase in the possibility of replicative error, which is itself more likely in FA patients. Generally speaking, difficult oral care and extensive dental caries are frequent in patients with GvHD. So, the tongue is often subjected to traumatic frictional damage on
sharp/rough teeth surfaces [24]. Repairing the DNA damage causes a potential increase in replicative error in this case as well. Nonetheless, it is worth to notice that oral tongue cancer incidence has been increasing worldwide [25, 26].

It therefore appears evident that an early and frequent screening is required in patients with FA, possibly by a multidisciplinary team. In fact, even constant dental monitoring could play a key role in the prevention of HNSCC. Unfortunately, the diagnostic delay in oral carcinomas is well documented [27]. Moreover, the present COVID-19 pandemic has increased the delays in oncologic diagnosis and treatments in the head and neck district [28]. As shown by Murillo et al., the onset of close cancer screening programs can lead to diagnose of SCC in stage I. Moreover, the follow-up has to be maintained lifelong because the cumulative incidence of SCC is up to 14% and 71% at 15 and 30 years, respectively [29].

Another key point in the pathophysiology of Fanconi anemia-related squamous cell carcinoma of head and neck (FA-HNSCC) is HCT. In order to grant a longer life expectancy and to prevent the development of leukemias, most FA patients undergo a HCT. Unluckily, patients treated with allogeneic HCT are at increased lifelong risk of developing malignancies. In the largest study to date to evaluate risk factors for solid cancers, Rizzo et al. studied a multi-institutional cohort of 28,874 allogeneic transplant recipients in which 189 solid malignancies were diagnosed over time. Overall, transplant recipients developed an invasive solid cancer at twice the rate expected based on population incidence rates. The risk reached threefold among patients followed for 15 years or more after transplantation. cGvHD and male sex were the main determinants for risk of malignancies. The most elevated excess absolute risk of developing solid cancer was observed for tumors of the oral cavity (overall 2.66 EAR, of which 1.08 tongue, 0.68 lip, 0.47 gum, and 0.43 salivary gland) [30]. GvHD is not present only in FA patients and it is one of the main risk factors for oral cancer [31, 32].

The therapeutic strategy is also very important in the management of HNSCC in patients affected by FA. The classic available weapons (surgery, radiotherapy, chemotherapy) must be well weighted. In fact, the predisposition to chromosomal instability of FA patients is related to an increased sensitivity to radiotherapy and chemotherapy [33], in which the resulting mucositis are really important, leading even to the interruption of the treatment. Furthermore, the poor DNA repair capacity of FA-affected cells does not guarantee a conspicuous replicative advantage over carcinoma cells. Therapies at lower doses or administered less frequently could be used, but with a consequent reduction in efficacy [34].

It is interesting to notice that those who present important collateral effects following radiotherapy or chemotherapy, especially young patients, should be genetically tested to exclude a FA-related mutation [35, 36].

Targeted chemo-therapy (such as cetuximab or gefitinib) or immuno-therapy (e.g., nivolumab, pembrolizumab) are definitely intriguing, but their actual efficacy and complication rates have still to be assessed overall [37]. It follows that the first-line therapeutic strategy is surgery. As demonstrated by Lee, patients with FA can also undergo major surgery without developing particular complications [37]. Conspicuous resective interventions are also possible, associated with reconstructive surgery which may include free flaps as well. However, the best strategy is to play in advance as in any cancer. The importance of frequent and early-onset screening is the key in the possibility of making diagnoses at an early stage [29]. So, the surgical resection of the tumor could be sufficient and effective as a treatment, possibly followed by reconstruction with local flaps. Careful preoperative planning must be performed in the treatment planning of any HNSCC, even with the aid of novel artificial intelligence tools, in order to ensure the preservation of noble structures [38, 39].

Another consideration should be made about local lymphatic surgery. From a therapeutic-diagnostic point of view, prophylactic nodal neck dissection in early (T1–T2) tongue cancers is still a controversial theme in non-FA patients [40, 41]. Namely, a prophylactic nodal neck dissection was not indicated in patient UPN 230, because the depth of invasion was less than or equal to 3 mm in all the specimens. As proposed by van Lanschot et al., a depth of invasion of at least 4 mm can be assumed as a key parameter to perform an elective node dissection in early stage oral cancer [42]. Moreover, it may be intentionally proposed to temporarily postpone nodal neck dissection in a FA-patient. In this way, an effective and predictable lymphatic drainage would be maintained in place. The card of nodal neck dissection could then be played later, given the predisposition to further HNSCC development in FA-patients. Nonetheless, a case-by-case approach should be adopted, together with a multidisciplinary board discussion.

In spite of progression in research and therapy, the prognosis still remains poor in FA-HNSCC patients, with about 50% mortality due to tumor progression in the first 2 to 3 years [12]. Considering the necessity of a close follow-up, adequate clinical and instrumental examinations are both required. Despite the sensitive improvement in radiation exposure when performing computed tomography scans, this aspect should also be taken in consideration in FA patients. Magnetic resonance imaging should therefore be preferred, especially when soft tissues have to be investigated. As already specified, close dental reevaluations should also be performed, looking for potential cancer threats [43, 44].
Conclusions

This study has identified five allotransplanted patients affected by Fanconi anemia with tongue cancer. The results of this paper indicate that TC can develop in a young age in this cohort of patients, even in absence of cGvHD. The precise mechanism of TC development remains to be elucidated, but key roles might be played by the oxidative stress, the short turnover time of tongue cells, and HCT. A close oral follow-up has to begin early and lifelong maintained, in order to detect and treat cancers with surgery at an early stage.

Author contribution All authors meet the ICMJE authorship criteria.
In particular:
M.D.B., A.A., A.N., L.C., and P.D.B. conceptualized and designed the study.
S.N., A.P., S.F., D.V., R.N., and S.A. acquired, analyzed, and interpreted the data.
M.D.B., S.N., A.P., D.V., and S.A. drafted the paper.
A.A., A.N., S.F., L.C., and P.D.B. revised the work critically for important intellectual content.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funding Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.

Declarations

Competing interests The authors declare no competing interests.

Institutional review board statement Due to the retrospective nature of this study, it was granted an exemption by the Institutional Review Board of the University Hospital of Modena, Italy. All procedures performed involving the human participant were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate Informed consent was obtained from all individuals participants included in the study.

Consent for publication The authors affirm that human research participants consented to the publication of their data and photographs.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kutler DI, Singh B, Satagopan J et al (2003) A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249–1256. https://doi.org/10.1182/blood-2002-07-2170
2. Furquim CP, Pivovar A, Amenábar JM et al (2018) Oral cancer in Fanconi anemia: review of 121 cases. Crit Rev Oncol Hematol 125:35–40. https://doi.org/10.1016/j.critrevonc.2018.02.013
3. Rosenberg PS, Alter BP, Ebell W (2008) Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 93:511–517. https://doi.org/10.3324/haematol.201234
4. Peffault de Latour R, Porcher R, Dalle J-H et al (2013) Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood 122:4279–4286. https://doi.org/10.1182/ blood-2013-01-479733
5. Di Bartolomeo P, Di Girolamo G, Olioso P et al (1992) Allogeneic bone marrow transplantation for Fanconi anemia. Bone Marrow Transpl 10:53–56
6. Deeg HJ, Socié G, Schoch G et al (1996) Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 87:386–392
7. Lee SJ, Vogelsang G, Flowers ME (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9:https://doi.org/10.1053/BBMT.2003.50026
8. Kutler DI, Auerbach AD, Satagopan J et al (2003) High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 129:106–112. https://doi.org/10.1001/archotol.129.1.106
9. Auerbach AD, Rogatko A, Schroeder-Kurth TM (1989) International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood 73:391–396
10. Glucksberg H, Storb R, Fefer A et al (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295–304. https://doi.org/10.1097/00007890-197410000-00001
11. American Joint Committee on Cancer (2017) AJCC cancer staging manual, 8th ed. Springer International Publishing
12. Risitano AM, Marotta S, Calzone R et al (2016) Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned. Haematologica 101:319–327. https://doi.org/10.3324/haematol.2015.133520
13. Kutler DI, Patel KR, Auerbach AD et al (2016) Natural history and management of Fanconi anemia patients with head and neck cancer: a 10-year follow-up. Laryngoscope 126:870–879. https://doi.org/10.1002/lary.25726
14. Hashibe M, Brennan P, Benhamou S et al (2007) Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99:777–789. https://doi.org/10.1093/jnci/djk179
15. Kesarwala AH, Krishna MC, Mitchell JB (2016) Oxidative stress in oral diseases. Oral Dis 22:9–18. https://doi.org/10.1111/odi.12300
16. Gonfloni S, Maiani E, Di Bartolomeo C et al (2012) Oxidative stress, DNA damage, and c-Abl signaling: at the crossroad in neurodegenerative diseases? Int J Cell Biol 2012:683097. https://doi.org/10.1155/2012/683097
17. Pagano G, Tiano L, Pallardó FV et al (2021) Re-definition and supporting evidence toward Fanconi anemia as a mitochondrial disease: prospects for new design in clinical management. Redox Biol 40:101860. https://doi.org/10.1016/j.redox.2021.101860
18. Cappelli E, Degan P, Dufour C, Ravera S (2018) Aerobic metabolism dysfunction as one of the links between Fanconi anemia-deficient pathway and the aggressive cell invasion in head and neck cancer cells. Oral Oncol 87:210–211. https://doi.org/10.1016/J. ORALONCOLOGY.2018.10.016

19. Anesi A, Di Bartolomeo M, Pellacani A et al (2020) Bone healing evaluation following different osteotomic techniques in animal models: a suitable method for clinical insights. Appl Sci 10:7165. https://doi.org/10.3390/app10207165

20. Guitton-Sert L, Gao Y, Masson J-Y (2021) Animal models of Fanconi anemia: a developmental and therapeutic perspective on a multifaceted disease. Semin Cell Dev Biol 113:113–131. https://doi.org/10.1016/j.semcdb.2020.11.010

21. Zhang Q, Deater M, Phan N, et al (2019) Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model. Pediatr Blood Cancer 66: https://doi.org/10.1002/PBC.27460

22. Barakat NJ, Toto PD, Choukas NC (1969) Ageing and cell renewal of oral epithelium. J Periodontol 40:599–602. https://doi.org/10.1902/jop.1969.40.10.599

23. Nanci A (2016) Ten Cate’s oral histology: development, structure, and function, 9th edn. Elsevier

24. Singhvi HR, Malik A, Chaturvedi P (2017) The role of chronic mucosal trauma in oral cancer: a review of literature. Indian J Med Paediatr Oncol 121:105451. https://doi.org/10.1016/j.ijc.2020.11.010

25. Deneuve S, Pérol O, Dantony E et al (2021) Diverging incidence trends of oral tongue cancer compared with other head and neck cancers in young adults in France. Int J Cancer. https://doi.org/10.1002/jic.33896

26. van Monsjou HS, Weesmann VB, van den Brekel MWM, Balm AJM (2013) Head and neck squamous cell carcinoma in young patients. Oral Oncol 49:1097–1102. https://doi.org/10.1016/J.ORALONCOLOGY.2013.09.001

27. Marella GL, Raschellà F, Solinas M et al (2018) The diagnostic delay of oral carcinoma. Ig Sanita Pubbl 74:249–263

28. Di Bartolomeo M, Pellacani A, Negrello S et al (2020) Emerging challenges and possible strategies in maxillo-facial and oral surgery during the COVID-19 pandemic. J Oral Sci 62:452–454. https://doi.org/10.2334/josnsud.20-0235

29. Maríllo-Sanjuán L, Balmañá J, de Pablo G-C et al (2021) Post-hematopoietic stem cell transplant squamous cell carcinoma in patients with Fanconi anemia: a dreadful enemy. Clin Transl Oncol. https://doi.org/10.1007/s12094-021-02693-8

30. Rizzo JD, Curtis RE, Socié G et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175–1183. https://doi.org/10.1182/blood-2008-05-158872

31. Chamoli A, Gosavi AS, Shirwadkar UP et al (2021) Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol 121:105451. https://doi.org/10.1016/J.ORALONCOLOGY.2021.105451

32. Sakthivel P, Ravendran S, Panda S, Singh CA (2021) Oral potential malignant disorders – a long list not to be forgotten. Oral Oncol 116:105244. https://doi.org/10.1016/J.ORALONCOLOGY.2021.105244

33. Nepal M, Che R, Zhang J et al (2017) Fanconi anemia signaling and cancer. Trends in cancer 3:840–856. https://doi.org/10.1016/j.trecan.2017.10.005

34. Beddok A, Krieger S, Castera L et al (2020) Management of Fanconi anemia patients with head and neck carcinoma: diagnosis and treatment adaptation. Oral Oncol 108:104816. https://doi.org/10.1016/j.oraloncology.2020.104816

35. Deng S, Ye W, Zhang S et al (2021) Oral tongue cancer in a patient with fanconi anemia: a case report and literature review. Cancer Manag Res 13:3145–3154. https://doi.org/10.2147/CMAR.S301582

36. Martin M, Saulois B (2021) Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene. Oral Oncol 112:104989. https://doi.org/10.1016/j.oraloncology.2020.104989

37. Lee RH, Kang H, Yom SS et al (2021) Treatment of Fanconi anemia-associated head and neck cancer: opportunities to improve outcomes. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-1259

38. Cipriano M, Allegretti S, Boleti F, et al (2022) Deep segmentation of the mandibular canal: a new 3D annotated dataset of CBCT volumes. IEEE Access PP:1–1. https://doi.org/10.1109/ACCESS.2022.3144840

39. Mercadante C, Cipriano M, Boleti F, et al (2021) A cone beam computed tomography annotation tool for automatic detection of the inferior alveolar nerve canal. In: Proceedings of the 16th International Joint Conference on Computer Vision, Imaging and Computer Graphics Theory and Applications. SCITEPRESS Sci Technol Publ 724–731

40. Hanai N, Asakage T, Kiyota N et al (2019) Controversies in relation to neck management in N0 early oral tongue cancer. Jpn J Clin Oncol 49:297–305. https://doi.org/10.1093/jjco/hyy196

41. Gillison ML, Haddad RI, Hicks WL, et al (2020) NCCN guidelines version 1.2021 head and neck cancers

42. van Lanschot CGF, Klazen YF, de Ridder MAJ et al (2020) Depth of invasion in early stage oral cavity squamous cell carcinoma: the optimal cut-off value for elective neck dissection. Oral Oncol 111:104940. https://doi.org/10.1016/J.ORALONCOLOGY.2020.104940

43. Fuentes Araujo RL, Amenabar Cespedes JM, Bonfim C et al (2013) PP024: oral malignant transformation in Fanconi Anemia siblings after bone marrow transplantation. Oral Oncol 49:S101. https://doi.org/10.1016/J.ORALONCOLOGY.2013.03.267

44. Cavalcanti LG, Lyko KF, Fuentes Araujo RL et al (2013) PP026: squamous cell carcinoma of the tongue in a Fanconi anemia patient. Oral Oncol 49:S102. https://doi.org/10.1016/J.ORALONCOLOGY.2013.03.269

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Mattia Di Bartolomeo¹ · Alexandre Anesi² · Arrigo Pellacani¹ · Sara Negrello³ · Annalisa Natale⁴ · Sabina Figurelli³ · Doriana Vaddinelli⁴ · Stefano Angelini⁵ · Luigi Chiarini² · Riccardo Nocini⁶ · Paolo Di Bartolomeo⁴

¹Surgery, Dentistry, Maternity and Infant Department, Unit of Dentistry and Maxillo-Facial Surgery, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy
²Department of Medical and Surgical Sciences for Children & Adults, Cranio-Maxillo-Facial Surgery, University of Modena and Reggio Emilia, Largo del Pozzo 71, 41124 Modena, Italy
³Cranio-Maxillo-Facial Surgery Unit, University Hospital of Modena, 41124 Modena, Italy
⁴Department of Oncology Hematology, Intensive Care and Bone Marrow Transplantation, Ospedale Civile, Pescara, Italy
⁵U.O.C. Hematology and Cellular Therapy, Ospedale Mazzoni, Ascoli Piceno, Italy
⁶Section of Ear, Nose and Throat (ENT), Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, 37129 Verona, Italy